Autolus Therapeutics plc Sustainability Profile
Autolus Therapeutics plc, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on developing innovative T cell therapies for cancer treatment. Founded in 2014, Autolus has rapidly established itself in the cell and gene therapy industry, with significant operational presence in Europe and the United States. The company is renowned for its proprietary technology platform, which enables the creation of next-generation T cell therapies designed to enhance patient outcomes. Autolus's lead product candidates, including AUTO1 and AUTO3, showcase unique mechanisms that target various malignancies, setting them apart in a competitive market. With a commitment to advancing cancer care, Autolus Therapeutics has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position as a leader in the field of immuno-oncology.
DitchCarbon Score
How does Autolus Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Autolus Therapeutics plc's score of 26 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Autolus Therapeutics plc's reported carbon emissions
Autolus Therapeutics plc, headquartered in Great Britain, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Autolus may not have established formal commitments to reduce its carbon footprint or may be in the early stages of developing such initiatives. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and climate action, often setting science-based targets to align with global climate goals. However, without specific emissions data or commitments, it is unclear how Autolus Therapeutics is positioning itself in relation to these industry standards.
How Carbon Intensive is Autolus Therapeutics plc's Industry?
How Carbon Intensive is Autolus Therapeutics plc's Location?
Autolus Therapeutics plc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Autolus Therapeutics plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
